Literature DB >> 19042022

Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase).

Kirk D C Jensen1, Eli E Sercarz, Claudia Raja Gabaglia.   

Abstract

Following Leishmania major infection, the early LACK (Leishmania homolog of receptors for activated C kinase)-induced IL-4 response appears to determine disease susceptibility in BALB/c mice. Therefore, we sought to manipulate the pathogenic T cell responses to the immunodominant epitope with the use of altered peptide ligands (APLs). Conservative and non-conservative substitutions for each amino acid of the LACK 161-175 peptide determinant were tested for their stimulatory capacity in four different LACK-reactive T cell systems. From these results, we propose a likely LACK 163-171/I-A(d) core peptide register and show that APLs with changes at putative T cell receptor (TCR) contacts provide the greatest potential for immune deviation. In particular, the TCR-contact H164V APL expanded Th1 cells upon in vitro recall of naïve splenocytes from LACK-specific BV4 T cell receptor transgenic mice and stimulated IFN-gamma secretion from a Th2-committed LACK-reactive T cell line. We also observed that non-conservative substitutions flanking the core determinant had strong agonistic effects for proliferation and Th1/Th2 modulation. However, upon immunization, the H164V APL considerably downregulated proliferation and cytokine responses to the wild type LACK 161-175 peptide, while immunization with the weak agonist, MHC contact APL S171K, increased the IFN-gamma/IL-4 ratio to the wild type peptide. In these instances, a hyporesponsive T cell response to the wild-type peptide was achieved by immunizing with an APL possessing non-conservative substitutions at TCR contact sites, while immune deviation was accomplished using a weak-agonist APL that retained the core determinant. Thus, certain LACK-APLs are able to induce T cell responses with a protective phenotype in an infectious disease such as leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19042022      PMCID: PMC2659654          DOI: 10.1016/j.molimm.2008.10.024

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  41 in total

Review 1.  Modulation of the immunogenicity of antigenic determinants by their flanking residues.

Authors:  K D Moudgil; E E Sercarz; I S Grewal
Journal:  Immunol Today       Date:  1998-05

2.  Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues.

Authors:  C A Scott; P A Peterson; L Teyton; I A Wilson
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

3.  T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.

Authors:  R T Carson; K M Vignali; D L Woodland; D A Vignali
Journal:  Immunity       Date:  1997-09       Impact factor: 31.745

4.  MHC genotype controls the capacity of ligand density to switch T helper (Th)-1/Th-2 priming in vivo.

Authors:  T Schountz; J P Kasselman; F A Martinson; L Brown; J S Murray
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

Review 5.  How the MHC selects Th1/Th2 immunity.

Authors:  J S Murray
Journal:  Immunol Today       Date:  1998-04

6.  Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells.

Authors:  V Kumar; V Bhardwaj; L Soares; J Alexander; A Sette; E Sercarz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

7.  Expression cloning of a protective Leishmania antigen.

Authors:  E Mougneau; F Altare; A E Wakil; S Zheng; T Coppola; Z E Wang; R Waldmann; R M Locksley; N Glaichenhaus
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

8.  Resistance to Leishmania major induced by tolerance to a single antigen.

Authors:  V Julia; M Rassoulzadegan; N Glaichenhaus
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

9.  The specificity and orientation of a TCR to its peptide-MHC class II ligands.

Authors:  D B Sant'Angelo; G Waterbury; P Preston-Hurlburt; S T Yoon; R Medzhitov; S C Hong; C A Janeway
Journal:  Immunity       Date:  1996-04       Impact factor: 31.745

10.  A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.

Authors:  C R Gabaglia; B Pedersen; M Hitt; N Burdin; E E Sercarz; F L Graham; J Gauldie; T A Braciak
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

View more
  6 in total

1.  A single-amino-acid variant of the H60 CD8 epitope generates specific immunity with diverse TCR recruitment.

Authors:  Su Jeong Ryu; Ji Yeong Jeon; Jun Chang; Thomas J Sproule; Derry C Roopenian; Eun Young Choi
Journal:  Mol Cells       Date:  2012-03-21       Impact factor: 5.034

2.  Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.

Authors:  Katharina Kronenberg; Sven Brosch; Florian Butsch; Yayoi Tada; Naotaka Shibagaki; Mark C Udey; Esther von Stebut
Journal:  J Invest Dermatol       Date:  2010-06-24       Impact factor: 8.551

3.  Receptor for activated C kinase ortholog of second-generation merozoite in Eimeria tenella: clone, characterization, and diclazuril-induced mRNA expression.

Authors:  Bian-hua Zhou; Xiao-jiong Shen; Hong-wei Wang; Tao Li; Fei-qun Xue
Journal:  Parasitol Res       Date:  2012-06-30       Impact factor: 2.289

4.  Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens.

Authors:  Ghodratollah Salehi-Sangani; Mehdi Mohebali; Vahid Jajarmi; Ali Khamesipour; Mojgan Bandehpour; Mahmoud Mahmoudi; Hadi Zahedi-Zavaram
Journal:  Iran J Basic Med Sci       Date:  2019-12       Impact factor: 2.699

5.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

6.  A Single Microorganism Epitope Attenuates the Development of Murine Autoimmune Arthritis: Regulation of Dendritic Cells via the Mannose Receptor.

Authors:  Fan Yang; Xuemei Fan; He Huang; Qiujie Dang; Hongwei Lei; Yang Li
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.